Traws Pharma

What Traws Pharma does

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Newtown, Pennsylvania, and listed on NASDAQ under the ticker TRAW. Formed in 2021 through Onconova Therapeutics' acquisition of Trawsfynydd Therapeutics, the company completed a strategic pivot from oncology to virology in 2025 and is now focused exclusively on developing oral small molecule antivirals targeting respiratory and emerging viral threats, including COVID-19, seasonal and avian influenza (H5N1), Hantavirus, Ebola, and Lassa fever.

Its lead programs are two novel oral antivirals. Ratutrelvir targets the SARS-CoV-2 Main protease (Mpro/3CL protease) in a ritonavir-independent formulation; in a 90-patient Phase 2 study versus PAXLOVID it demonstrated 10% adverse events versus 23.3% and no viral rebounds. Tivoxavir marboxil (TXM) targets the influenza cap-dependent endonuclease (CEN) and is positioned as both a single-dose treatment and once-monthly oral prophylactic, supported by broad in vitro activity across seasonal strains and a tablet formulation showing 30% higher exposure than prototype. A third program is a broad-spectrum combination agent using a dual-strike mechanism (host nucleotide depletion plus forced lethal incorporation) for Hantavirus, Ebola, and Lassa fever, with non-clinical work at BSL-3/BSL-4 labs. Legacy oncology assets rigosertib and narazaciclib are being out-licensed.

Traws Pharma is pre-revenue on a product basis and reports $2.8 million of 2025 revenue and a $7.1 million Q1 2026 net loss. Its go-to-market is clinical development through FDA, UK MHRA, and Australian pathways, combined with government-channel positioning via BARDA, CDC, NAFDAC, and the African Medicines Agency for pandemic stockpiling. The company has 51-100 employees, a cash runway stated to extend into Q1 2027, and is led by former CDC Director Robert R. Redfield (CMO), Iain Dukes (CEO; former Merck BD&L head and OrbiMed Venture Partner), and C. David Pauza (CSO; 30+ US patents). Recent regulatory setbacks — an FDA clinical hold on TXM (February 2026) and an MHRA negative review of the Phase 2a challenge study (June 2026) — have driven the stock to a new 52-week low and increased reliance on a $10 million PIPE plus up to $50 million of milestone-based warrants closed in April 2026.

Name

Traws Pharma

Legal name

Traws Pharma, Inc.

Website

https://trawspharma.com

Company type

Public

Founded year

2021

Operating status

Operating

Headcount range

51–100 employees

Short description

Traws Pharma is a clinical-stage biopharmaceutical company developing oral small molecule antivirals for COVID-19, seasonal and avian influenza, and emerging viral threats like Hantavirus, Ebola, and Lassa fever, pursuing regulatory pathways with FDA, MHRA, and government stockpiling agencies.

Ownership category

akta.pro rank

Product category

Antiviral Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

akta.pro secondary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Antiviral drug development
• Respiratory disease therapeutics
• Small molecule antivirals
• Clinical stage biopharmaceutical
• Infectious disease treatment

Headquarters

HQ city

Newtown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure

Revenue model

1. Product Revenue: Pre-revenue clinical stage company. No approved products currently. Revenue expected from future product launches for COVID-19 and influenza treatments upon regulatory approval.
2. Strategic Partnerships and Licensing: Revenue potential from licensing agreements and development partnerships. Currently seeking development and commercialization partners for legacy clinical oncology programs (rigosertib and narazaciclib). BARDA engagement for pandemic influenza stockpile inclusion.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Traws Pharma is a clinical-stage biopharmaceutical company developing two novel investigational oral small molecule antivirals targeting respiratory viral diseases: ratutrelvir for COVID-19 (a ritonavir-independent Mpro/3CL protease inhibitor) and tivoxavir marboxil for bird flu and seasonal influenza (a cap-dependent endonuclease inhibitor). The company is also advancing a broad-spectrum antiviral combination agent for Hantavirus, Ebola, and Lassa fever using a dual-strike mechanism.

Product overview

Traws Pharma is a clinical-stage biopharmaceutical company advancing two novel investigational oral small molecule antivirals. Ratutrelvir is in development as a ritonavir-independent COVID-19 treatment targeting the Main protease (Mpro/3CL protease). Tivoxavir marboxil is being developed as a single-dose treatment and once-monthly prophylactic for bird flu and seasonal influenza, targeting the influenza cap-dependent endonuclease (CEN). The company is also advancing a broad-spectrum antiviral combination agent targeting Hantavirus, Ebola, and Lassa fever. Legacy oncology programs (Narazaciclib and Rigosertib) are available for partnering.

Differentiator

Problem solved

Functional benefit

Products and services

• Ratutrelvir An investigational oral ritonavir-free COVID-19 treatment targeting the Main protease (Mpro or 3CL protease). Developed as an alternative to PAXLOVID with demonstrated fewer adverse events (10% vs 23.3%) and no viral rebounds in Phase 2 clinical studies.
• Tivoxavir Marboxil (TXM) An investigational single-dose oral antiviral for bird flu and seasonal influenza, targeting the influenza cap-dependent endonuclease (CEN). Demonstrated broad in vitro efficacy across multiple seasonal influenza strains with a pharmacokinetic profile suitable for oral chemoprophylaxis. Also being developed as once-monthly oral prophylactic for influenza.
• Broad-Spectrum Antiviral Combination Agent A novel dual-strike broad-spectrum antiviral targeting Hantavirus, Ebola, and Lassa fever. The mechanism combines host nucleotide depletion with forced lethal incorporation of the drug into viral replication. Components have been safely evaluated in human studies as single agents, with non-clinical evaluation underway at BSL-3 and BSL-4 laboratories.
• Narazaciclib A CDK4/6 inhibitor being developed to overcome resistance in metastatic breast cancer and other hard-to-treat tumors. Traws Pharma is actively seeking development and commercialization partners for this legacy oncology program.
• Rigosertib A small molecule kinase inhibitor including PLK-1 for oncology applications. Traws Pharma is actively seeking development and commercialization partners for this legacy clinical oncology program.

Quantifiable outcome

• Fewer adverse events: 10% for ratutrelvir vs 23.3% for PAXLOVID
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• hVIVOcoreStrategic or Co-development Partner · 14 April 2026Clinical trial agreement for Phase 2a influenza human challenge study of tivoxavir marboxil. Randomized, double-blinded, placebo-controlled trial to enroll approximately 150 participants at hVIVO's Canary Wharf facilities. Will assess safety, tolerability, and effectiveness of the oral antiviral for seasonal influenza and bird flu. Revenue expected to be recognized in H1 2026.
• ChemDivcoreImplementation/ SI/ Consulting Partner · 30 October 2025Extended CMC (Chemistry, Manufacturing and Controls) services collaboration for ratutrelvir. Collaboration includes manufacturing, medicinal chemistry, and predictive pharmacology services to support clinical and regulatory progress for Phase 2 trials.
• Expert Systems Inc.minorImplementation/ SI/ Consulting Partner · 22 October 2025Life sciences accelerator supporting Phase 2 clinical studies of ratutrelvir. AI-driven molecular modeling used in development of the novel ritonavir-free antiviral for COVID-19.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• Cidara Therapeutics: Cidara is a clinical-stage biotech developing antiviral conjugates and immunotherapies for serious viral infections including influenza and COVID-19. Comparable small-cap clinical antiviral company with similar regulatory pathway challenges.
• Vir Biotechnology: Vir Biotechnology focuses on infectious disease therapeutics including influenza and COVID-19 antibodies and small molecules. Comparable emerging biotech in respiratory antiviral development with broader infectious disease pipeline.
• Arcturus Therapeutics: Arcturus is a clinical-stage biotech developing mRNA and antiviral therapeutics including COVID-19 and influenza candidates. Comparable clinical-stage infectious disease company with overlapping respiratory virus pipeline.

Direct peers

• Roche: Roche markets XOFLUZA (baloxavir marboxil), a single-dose oral cap-dependent endonuclease inhibitor for influenza — the same mechanism as Traws's tivoxavir marboxil. Direct mechanistic competitor in the influenza antiviral space.
• Atea Pharmaceuticals: Atea developed bemnifosbuvir, an oral COVID-19 antiviral in late-stage development. Closely comparable clinical-stage antiviral company competing in the same oral COVID treatment market as ratutrelvir.
• BioCryst Pharmaceuticals: BioCryst markets RAPIACTA (peramivir) for influenza and is developing oral influenza antivirals. Direct competitor in the influenza antiviral space with commercial-stage experience and similar regulatory pathway.
• Shionogi: Shionogi developed XOCOVA (ensitrelvir), an oral 3CL protease inhibitor for COVID-19 approved in Japan. Competes in the same Mpro inhibitor space as Traws's ratutrelvir and represents a non-ritonavir COVID antiviral alternative.
• Pfizer: Pfizer markets PAXLOVID (nirmatrelvir/ritonavir), the dominant oral COVID-19 antiviral and the comparator in Traws's ratutrelvir Phase 2 study. Direct head-to-head competition in the COVID antiviral category with established commercial scale.

Broad incumbents

• GSK: GSK has a long history in influenza antivirals (RELENZA) and broader respiratory/infectious disease portfolio. Broad incumbent player with overlapping vaccine and antiviral capabilities relevant to Traws's target indications.
• Merck: Merck developed LAGEVRIO (molnupiravir), an oral COVID-19 antiviral, and has deep antiviral R&D capabilities across influenza, HIV, and HCV. Represents broad incumbent competition in respiratory antiviral development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Traws Pharma